Institut Jules Bordet
- Address
- lock Available on a paid plan
Institut Jules Bordet - Leading European Oncology Research Center
Institut Jules Bordet stands as a premier cancer research institution specializing in comprehensive clinical trials across multiple oncology disciplines. The center demonstrates exceptional expertise in breast cancer research, conducting advanced studies in HER2-positive, hormone receptor-positive, and triple-negative breast cancer subtypes, utilizing cutting-edge therapeutics including antibody-drug conjugates, CDK4/6 inhibitors, and novel targeted therapies.
- Breast Cancer: HER2-targeted therapies, hormone receptor-positive disease, neoadjuvant and adjuvant immunotherapy combinations
- Gastrointestinal Malignancies: Colorectal cancer with KRAS mutations and MSS subtypes, gastric and esophageal adenocarcinomas, pancreatic ductal adenocarcinoma
- Genitourinary Cancers: Metastatic castration-resistant prostate cancer, renal cell carcinoma, urothelial carcinoma with novel radioligand and immunotherapy approaches
- Hematologic Malignancies: Acute lymphoblastic leukemia, myelodysplastic syndromes, acute myeloid leukemia, and allogeneic stem cell transplantation studies
The institute maintains a robust portfolio of phase I-III clinical trials investigating immunotherapy combinations, antibody-drug conjugates, and precision medicine approaches across solid tumors and blood cancers. Research focus areas include biomarker-driven patient selection for KRAS mutations, PTEN deficiency, MMR status, and HER2 expression, alongside innovative studies in lung cancer, gynecologic malignancies, lymphomas, and advanced therapeutic modalities including CAR-T cell therapy and radioligand therapy. The center's commitment to translational research and systems biology approaches positions it at the forefront of personalized cancer treatment development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 23 therapeutic areas and 15 of 322 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 314 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 80 by active trials.
- 1Institut Jules Bordet6active
lock +79 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB14trials
lock +41 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Jules Bordet
lock Showing 1 of 246 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications | MaaT PHARMA | Phase II | Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 322 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 24 | Unknown | 2016-01-11 | 2026-07-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.